CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Shares withheld for taxes Chief Executive Officer gave up 20,655 shares (to pay taxes)
- 4 Grant or award Chief Scientific Officer acquired 40,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Gift Chief Scientific Officer gave 24,158 shares (gift)
- 4 Open-market buy Director bought 17,000 shares at $9.88 ($167,943)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $10.29 ($51,448)
- 4 Planned sale Chief Medical Officer sold 10,628 shares at an average $19.50 ($207,298)
- 4 Planned sale Chief Scientific Officer sold 6,068 shares at an average $19.50 ($118,355)
- 4 Planned sale Chief Financial Officer sold 5,482 shares at an average $19.50 ($106,926)
- 4 Planned sale Director sold 5,000 shares at $25.05 ($125,238)
- 4 Open-market buy 10% owner bought 4,760,000 shares at $22.66 ($107,861,600)
- 4 Grant or award Director acquired 19,059 shares (grant or award)
- 4 Grant or award Director acquired 16,364 shares (grant or award)
- 4 Grant or award Director acquired 16,364 shares (grant or award)
- 4 Planned sale President sold 27,768 shares at an average $26.27 ($729,506)
- 4 Planned sale Chief Scientific Officer sold 80,000 shares at $30.02 ($2,401,248)
- 4 Grant or award Director acquired 39,732 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Operating Officer acquired 52,500 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 7,851 shares at an average $20.13 ($158,005)
Page 4 of 13 · 252 filings